$97.62-1.61 (-1.62%)
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide.
MetLife, Inc. in the Financial Services sector is trading at $97.62 with a market capitalization of $62.0B. Wall Street consensus targets $105.06 (16 analysts), implying a +7.6% move over the next 12 months. The stock is currently near its 52-week high of $100.93, remaining 20.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $18.62B↓ | $23.29B↑ | $16.88B↓ | $17.18B↓ | $18.29B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.77B↑ | $1.38B↓ | $1.48B↑ | $1.25B↓ | $1.61B |
| Net Income | $1.19B↑ | $809.00M↓ | $896.00M↑ | $729.00M↓ | $945.00M |
MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Mid...

MetLife has outperformed the broader market over the past year, while analysts remain somewhat bullish on its future prospects.

MET's diversified portfolio, strong cash generation and global growth support premium gains, while investment income volatility remains a key risk.

Chariot Re said the new capital will help it scale its life and annuity reinsurance business and pursue a growing pipeline of diversified opportunities.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

SanDisk, Phillips 66, and MetLife added $27 billion in combined buyback capacity, with SanDisk's $14 billion authorization following a 500% share price surge in 2026.
Academic risk and quality models computed from MET's own filings and price history, not from analyst opinion.
Mixed: 4 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z below 1.81, the financial-distress band. This measures balance-sheet stress, not share-price direction.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.